Aeglea BioTherapeutics Files For $86.25M IPO

Austin-based Aeglea BioTherapeutics filed for an IPO on Wednesday, saying that it is hoping to raise up to $86.25M in an IPO on the NASDAQ Global Market. The company has applied to list as AGLE. The biopharmaceuticals firm, which is looking to treat metabolic diseases, is led by David Lowe. The IPO is being underwritten by Cowen and Company, UBS Investment Bank, BMO Capital Markets, and Wedbush PacGrow; the company is venture backed by Lilly Ventures Fund, Novartis Bioventures, OrbiMed, Jennison Global Healthcare Master Fund, along with others.